Liver-targeted Angptl4 silencing by antisense oligonucleotide treatment attenuates hyperlipidemia and atherosclerosis development in APOE*3-Leiden.CETP mice.

Melanie Modder Wietse In Het PanhuisMohan LiSalwa AfkirAlexandra L DornAmanda C M PronkTrea C M StreeflandReshma A LalaiStefan Pierrou Stefan K Nilsson Gunilla Olivecrona Sander Kooijman Patrick C N Rensen Milena Schönke

Published in: Cardiovascular research (2024)

Liver-targeted Angptl4 silencing potently attenuates hyperlipidemia and atherosclerosis development in APOE*3-Leiden.CETP mice, and liver-targeted ANGPTL4 silencing is well-tolerated in non-human primates. These data warrant further clinical development of liver-targeted ANGPTL4 silencing.

Keyphrases

cancer therapy
high fat diet
high fat diet induced
cardiovascular disease
endothelial cells
cognitive decline
type diabetes
drug delivery
insulin resistance
metabolic syndrome
deep learning
smoking cessation